Abstract
Non-Muscle Invasive Bladder Cancer (NMIBC) is one of the major challenges in oncology, characterized by high recurrence and progression rates, particularly in patients refractory to BCG immunotherapy. Approximately 50% of patients fail to respond to BCG treatment, facing limited therapeutic options and a significant risk of progression to more aggressive stages. This project proposes an i…